Other · developed by Zai Lab Co.
ZL-1109 is a subcutaneously injected agent studied in thyroid eye disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07211776 | Phase 3 | Thyroid Eye Disease (TED) | Active not recruiting | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Thyroid Eye Disease (TED)
Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.
See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZLAB catalysts and pipeline →